Chevy Chase Trust Holdings Inc. boosted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 194,893 shares of the biopharmaceutical company’s stock after buying an additional 1,197 shares during the period. Chevy Chase Trust Holdings Inc. owned 0.09% of Alexion Pharmaceuticals worth $27,342,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALXN. Fiduciary Trust Co. purchased a new stake in Alexion Pharmaceuticals in the second quarter valued at $111,000. Penserra Capital Management LLC raised its position in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Dupont Capital Management Corp purchased a new stake in Alexion Pharmaceuticals in the third quarter valued at $156,000. Acadian Asset Management LLC purchased a new stake in Alexion Pharmaceuticals in the second quarter valued at $160,000. Finally, BT Investment Management Ltd purchased a new stake in Alexion Pharmaceuticals in the third quarter valued at $165,000. 94.16% of the stock is currently owned by institutional investors.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $114.46 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $23,855.68, a price-to-earnings ratio of 21.84, a P/E/G ratio of 1.16 and a beta of 1.18. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.23 EPS. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.
ALXN has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Royal Bank Of Canada lifted their target price on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Stifel Nicolaus reduced their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $154.49.
COPYRIGHT VIOLATION WARNING: “Chevy Chase Trust Holdings Inc. Buys 1,197 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/10/chevy-chase-trust-holdings-inc-buys-1197-shares-of-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.